Wire · opportunities
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
Sonrotoclax received FDA accelerated approval in May 2026 as the first BCL2 inhibitor for relapsed/refractory mantle cell lymphoma (MCL), offering a new oral treatment option particularly for patients after BTK inhibitors such as pirtobrutinib. Ongoing phase 3 trials are evaluating sonrotoclax in combination with zanubrutinib and other therapies to expand treatment possibilities.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have an oral treatment approved that opens new therapy combinations and options post-BTK inhibitors in MCL. Move quickly to explore sonrotoclax as a bridge to CAR T-cell therapy or in combination regimens to capture this underserved patient segment.
◆ Coverage
1 source · 4 Sep 2026
◆ Related on Wire
◆ Topics